| Code | CSB-RA013510MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to TST-004, designed for research targeting MASP2 (Mannan-binding lectin serine protease 2). MASP2 is a critical effector enzyme of the lectin pathway of complement activation, functioning as the primary protease that cleaves C4 and C2 to initiate the complement cascade. This serine protease plays a pivotal role in innate immunity and inflammatory responses. Dysregulated MASP2 activity has been implicated in various pathological conditions, including ischemia-reperfusion injury, thrombotic microangiopathies, age-related macular degeneration, and antibody-mediated transplant rejection, making it an important therapeutic target for complement-mediated disorders.
TST-004 (narsoplimab) is a fully humanized IgG4 monoclonal antibody that specifically inhibits MASP2, thereby blocking lectin pathway-mediated complement activation while preserving the classical and alternative pathways. This biosimilar antibody provides researchers with a valuable tool for investigating lectin pathway mechanisms, studying complement-mediated pathologies, and exploring potential therapeutic interventions in inflammatory and autoimmune diseases.
There are currently no reviews for this product.